Armata Pharmaceuticals (ARMP) Short term Debt (2018 - 2025)

Armata Pharmaceuticals (ARMP) reported Short term Debt of $48.1 million for Q3 2025, up 16.28% on a YoY basis from $41.4 million in Q3 2024, and up 43.78% sequentially from $33.4 million in Q2 2025.

Armata Pharmaceuticals (ARMP) Short term Debt (2018 - 2025) Analysis & Trends

Armata Pharmaceuticals (ARMP) has 5 years of Short term Debt data on file, last reported at $48.1 million in Q3 2025.

  • For the quarter ending Q3 2025, Short term Debt rose 16.28% year-over-year to $48.1 million; the trailing twelve-month figure through Sep 2025 stood at $48.1 million (up 16.28% YoY), and the FY2020 full-year result was $1.9 million, up 100.0% from the prior year.
  • Short term Debt rose to $48.1 million in Q3 2025, from $33.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $71.7 million in Q1 2024 to a low of $27.7 million in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Armata Pharmaceuticals 191.29 Mn 186.49 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 48.09 Mn
Jun 30, 2025 33.45 Mn
Mar 31, 2025 27.69 Mn
Sep 30, 2024 41.36 Mn
Jun 30, 2024 48.26 Mn
Mar 31, 2024 71.66 Mn
Dec 31, 2020 1.94 Mn
Sep 30, 2020 1.77 Mn
Jun 30, 2020 1.62 Mn
Mar 31, 2020 1.48 Mn
Dec 31, 2019 970,000.00
Sep 30, 2019 885,000.00
Jun 30, 2019 769,000.00
Dec 31, 2018 970,000.00